BTK and cancer: Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase (BTK), FLT3, BCL-2, IDHs, have fundamentally transformed the landscape of cancer therapy from cytotoxic chemotherapy to biomarker-driven precision therapy [15, 16].